Pyomyositis as Presentation of Chemoport-related Infection in Breast Carcinoma: 18F-FDG PET/CT Findings
PDF
Cite
Share
Request
Interesting Image
VOLUME: 34 ISSUE: 1
P: 76 - 78
February 2025

Pyomyositis as Presentation of Chemoport-related Infection in Breast Carcinoma: 18F-FDG PET/CT Findings

Mol Imaging Radionucl Ther 2025;34(1):76-78
1. All India Institute of Medical Sciences (AIIIMS), Rishikesh, India
2. Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, India
No information available.
No information available
Received Date: 20.05.2024
Accepted Date: 21.07.2024
Online Date: 07.02.2025
Publish Date: 07.02.2025
PDF
Cite
Share
Request

Abstract

A Chemoport is frequently utilized in oncological patients for administering chemotherapy. However, inadequate care can lead to various infectious and non-infectious complications. Infection commonly presents as a local infection that can lead to life-threatening septicemia. Early diagnosis and intervention are necessary to reduce morbidity and mortality. We report a patient with breast cancer who underwent 18F-fluorodeoxyglucose positron (18F-FDG) positron emission tomography/computed tomography (PET/CT) due to suspicion of metastatic disease. 18F-FDG-PET/CT revealed pyomyositis involving multiple skeletal muscles and septic emboli in the lungs and identified the chemoport as a possible source of infection. The infection source was confirmed and the patient responded to anti-microbiological therapy.

Keywords:
Chemoport-related infection, breast cancer, 18F-FDG PET/CT, pyomyositis, methicillin-resistant staphylococcus aureus

Ethics

Informed Consent: Informed consent was obtained.

Authorship Contributions

Concept: V.S., M.O., Design: V.S., D.S., N.K., M.O., S.G., Data Collection or Processing: V.S., D.S., N.K., M.O., S.G., Analysis or Interpretation: V.S., D.S., N.K., M.O., S.G., Literature Search: V.S., M.O., Writing: V.S., M.O.
Conflict of Interest: No conflicts of interest were declared by the authors.
Financial Disclosure: The authors declare that this study has received no financial support.

References

1
Machat S, Eisenhuber E, Pfarl G, Lenz K, Payer F, Duran C, Längle F, Reiner CS, Ketteler H, Betz M. Complications of central venous port systems: a pictorial review. Insights Imaging. 2019;10:86.
2
Mittal GS, Sundriyal D, Naik NB, Bansal D, Khandelwal N, Singh K, Rathi A, Gupta A, Kapoor R. Totally implantable venous access device (Chemoport) in oncology: study of 168 polyurethane Chemoport catheter system. South Asian J Cancer. 2021;10:261-4.
3
Aparna S, Ramesh S, Appaji L, Ghosh P, Chatterjee N, Manohar S. Complications of Chemoport in children with cancer: Experience of 54,100 catheter days from a tertiary cancer center of Southern India. South Asian J Cancer. 2015;4:143-5.
4
Sousa B, Furlanetto J, Hutka M, Baggott S, Bassam T, Chiappino C, Mavri V. ESMO Guidelines committee. Central venous access in oncology: ESMO clinical practice guidelines. Ann Oncol. 2015;26:152-68.
5
Wang TY, Lee KD, Chen PT, Lai JH, Chang MC, Su HC, Lee YC, Chang YT. Incidence and risk factors for central venous access port-related infection in Chinese cancer patients. J Formos Med Assoc. 2015;114:1055-60.
6
Nakayama Y, Sugiyama A, Yamamoto T, Matsumoto Y, Kinoshita A, Mori N, Sakamoto M. Pyomyositis in a patient undergoing chemotherapy for gastric cancer: a case report and literature review. Case Rep Oncol. 2021;14:1220-7.